From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy - PubMed (original) (raw)
Review
From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy
Gunter Wolf et al. Diabetes. 2005 Jun.
Abstract
Nephropathy is a major complication of diabetes. Alterations of mesangial cells have traditionally been the focus of research in deciphering molecular mechanisms of diabetic nephropathy. Injury of podocytes, if recognized at all, has been considered a late consequence caused by increasing proteinuria rather than an event inciting diabetic nephropathy. However, recent biopsy studies in humans have provided evidence that podocytes are functionally and structurally injured very early in the natural history of diabetic nephropathy. The diabetic milieu, represented by hyperglycemia, nonenzymatically glycated proteins, and mechanical stress associated with hypertension, causes downregulation of nephrin, an important protein of the slit diaphragm with antiapoptotic signaling properties. The loss of nephrin leads to foot process effacement of podocytes and increased proteinuria. A key mediator of nephrin suppression is angiotensin II (ANG II), which can activate other cytokine pathways such as transforming growth factor-beta (TGF-beta) and vascular endothelial growth factor (VEGF) systems. TGF-beta1 causes an increase in mesangial matrix deposition and glomerular basement membrane (GBM) thickening and may promote podocyte apoptosis or detachment. As a result, the denuded GBM adheres to Bowman's capsule, initiating the development of glomerulosclerosis. VEGF is both produced by and acts upon the podocyte in an autocrine manner to modulate podocyte function, including the synthesis of GBM components. Through its effects on podocyte biology, glomerular hemodynamics, and capillary endothelial permeability, VEGF likely plays an important role in diabetic albuminuria. The mainstays of therapy, glycemic control and inhibition of ANG II, are key measures to prevent early podocyte injury and the subsequent development of diabetic nephropathy.
Similar articles
- Cellular and molecular mechanisms of proteinuria in diabetic nephropathy.
Wolf G, Ziyadeh FN. Wolf G, et al. Nephron Physiol. 2007;106(2):p26-31. doi: 10.1159/000101797. Epub 2007 Jun 6. Nephron Physiol. 2007. PMID: 17570945 Review. - Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy.
Ziyadeh FN, Wolf G. Ziyadeh FN, et al. Curr Diabetes Rev. 2008 Feb;4(1):39-45. doi: 10.2174/157339908783502370. Curr Diabetes Rev. 2008. PMID: 18220694 Review. - Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology.
Gruden G, Perin PC, Camussi G. Gruden G, et al. Curr Diabetes Rev. 2005 Feb;1(1):27-40. doi: 10.2174/1573399052952622. Curr Diabetes Rev. 2005. PMID: 18220580 Review. - Podocyte biology in diabetic nephropathy.
Li JJ, Kwak SJ, Jung DS, Kim JJ, Yoo TH, Ryu DR, Han SH, Choi HY, Lee JE, Moon SJ, Kim DK, Han DS, Kang SW. Li JJ, et al. Kidney Int Suppl. 2007 Aug;(106):S36-42. doi: 10.1038/sj.ki.5002384. Kidney Int Suppl. 2007. PMID: 17653209 Review. - Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy.
Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K, Lovato T, Richardson M, Myers BD, Nelson RG. Weil EJ, et al. Kidney Int. 2012 Nov;82(9):1010-7. doi: 10.1038/ki.2012.234. Epub 2012 Jun 20. Kidney Int. 2012. PMID: 22718189 Free PMC article. Clinical Trial.
Cited by
- Renal handling of albumin in rats with early stage diabetes: A theoretical analysis.
Edwards A. Edwards A. J Physiol. 2024 Jul;602(14):3575-3592. doi: 10.1113/JP286245. Epub 2024 Jun 10. J Physiol. 2024. PMID: 38857419 - Characterizing Glomerular Barrier Dysfunction with Patient-Derived Serum in Glomerulus-on-a-Chip Models: Unveiling New Insights into Glomerulonephritis.
Kim SY, Choi YY, Kwon EJ, Seo S, Kim WY, Park SH, Park S, Chin HJ, Na KY, Kim S. Kim SY, et al. Int J Mol Sci. 2024 May 8;25(10):5121. doi: 10.3390/ijms25105121. Int J Mol Sci. 2024. PMID: 38791159 Free PMC article. - Promoting mitochondrial dynamics by inhibiting the PINK1-PRKN pathway to relieve diabetic nephropathy.
Zhu JY, van de Leemput J, Han Z. Zhu JY, et al. Dis Model Mech. 2024 Apr 1;17(4):dmm050471. doi: 10.1242/dmm.050471. Epub 2024 May 1. Dis Model Mech. 2024. PMID: 38602042 Free PMC article. - Mechanisms of inflammation modulation by different immune cells in hypertensive nephropathy.
Hao XM, Liu Y, Hailaiti D, Gong Y, Zhang XD, Yue BN, Liu JP, Wu XL, Yang KZ, Wang J, Liu QG. Hao XM, et al. Front Immunol. 2024 Mar 13;15:1333170. doi: 10.3389/fimmu.2024.1333170. eCollection 2024. Front Immunol. 2024. PMID: 38545112 Free PMC article. Review. - Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway.
Sun J, Zhang X, Wang S, Chen D, Shu J, Chong N, Wang Q, Xu Y. Sun J, et al. Diabetol Metab Syndr. 2024 Feb 7;16(1):38. doi: 10.1186/s13098-024-01271-6. Diabetol Metab Syndr. 2024. PMID: 38326870 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous